- United States
Cyclo Therapeutics Full Year 2022 Earnings: Misses Expectations
Cyclo Therapeutics (NASDAQ:CYTH) Full Year 2022 Results
Key Financial Results
- Revenue: US$1.38m (down 13% from FY 2021).
- Net loss: US$15.5m (loss widened by 8.1% from FY 2021).
- US$1.83 loss per share.
All figures shown in the chart above are for the trailing 12 month (TTM) period
Cyclo Therapeutics Revenues and Earnings Miss Expectations
Revenue missed analyst estimates by 42%. Earnings per share (EPS) also missed analyst estimates by 30%.
Looking ahead, revenue is forecast to grow 61% p.a. on average during the next 3 years, compared to a 14% growth forecast for the Biotechs industry in the US.
Performance of the American Biotechs industry.
The company's shares are down 5.9% from a week ago.
What about risks? Every company has them, and we've spotted 6 warning signs for Cyclo Therapeutics (of which 1 can't be ignored!) you should know about.
Valuation is complex, but we're helping make it simple.
Find out whether Cyclo Therapeutics is potentially over or undervalued by checking out our comprehensive analysis, which includes fair value estimates, risks and warnings, dividends, insider transactions and financial health.View the Free Analysis
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Cyclo Therapeutics, Inc., a clinical stage biotechnology company, develops cyclodextrin-based products for the treatment of neurodegenerative diseases.
Adequate balance sheet and fair value.